These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32452588)

  • 1. A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma.
    Roth MT; Cardin DB; Borazanci EH; Steinbach M; Picozzi VJ; Rosemury A; Wadlow RC; Newman RA; Berlin J
    Oncologist; 2020 Oct; 25(10):e1446-e1450. PubMed ID: 32452588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.
    Hong DS; Henary H; Falchook GS; Naing A; Fu S; Moulder S; Wheler JJ; Tsimberidou A; Durand JB; Khan R; Yang P; Johansen M; Newman RA; Kurzrock R
    Invest New Drugs; 2014 Dec; 32(6):1204-12. PubMed ID: 24919855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway.
    Pan Y; Rhea P; Tan L; Cartwright C; Lee HJ; Ravoori MK; Addington C; Gagea M; Kundra V; Kim SJ; Newman RA; Yang P
    Invest New Drugs; 2015 Apr; 33(2):271-9. PubMed ID: 25476893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Botanical Drug PBI-05204, a Supercritical CO
    Colapietro A; Yang P; Rossetti A; Mancini A; Vitale F; Martellucci S; Conway TL; Chakraborty S; Marampon F; Mattei V; Gravina GL; Biordi AL; Wei D; Newman RA; Festuccia C
    Front Pharmacol; 2020; 11():552428. PubMed ID: 33013390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
    Reni M; Balzano G; Zanon S; Zerbi A; Rimassa L; Castoldi R; Pinelli D; Mosconi S; Doglioni C; Chiaravalli M; Pircher C; Arcidiacono PG; Torri V; Maggiora P; Ceraulo D; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):413-423. PubMed ID: 29625841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
    Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
    Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
    Ko AH; Bekaii-Saab T; Van Ziffle J; Mirzoeva OM; Joseph NM; Talasaz A; Kuhn P; Tempero MA; Collisson EA; Kelley RK; Venook AP; Dito E; Ong A; Ziyeh S; Courtin R; Linetskaya R; Tahiri S; Korn WM
    Clin Cancer Res; 2016 Jan; 22(1):61-8. PubMed ID: 26251290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Botanical Drug PBI-05204, a Supercritical CO
    Colapietro A; Yang P; Rossetti A; Mancini A; Vitale F; Chakraborty S; Martellucci S; Marampon F; Mattei V; Gravina GL; Iorio R; Newman RA; Festuccia C
    Front Pharmacol; 2022; 13():852941. PubMed ID: 35401175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
    BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.
    Aggarwal C; Cohen RB; Yu E; Hwang WT; Bauml JM; Alley E; Evans TL; Langer CJ
    Clin Lung Cancer; 2018 Mar; 19(2):157-162. PubMed ID: 29129435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
    George TJ; Ali A; Wang Y; Lee JH; Ivey AM; DeRemer D; Daily KC; Allegra CJ; Hughes SJ; Fan ZH; Cameron ME; Judge AR; Trevino JG
    Oncologist; 2021 Oct; 26(10):825-e1674. PubMed ID: 34101295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
    Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
    Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oleandrin and PBI-05204 against bovine viruses of importance to commercial cattle health.
    Newman RA; Chase CCL; Matos JR; Abdelsalam K; Buterbaugh R; Van Holland S; Abdelaal H; Woolum A; Jagannadha Sastry K
    Antivir Chem Chemother; 2022; 30():20402066221103960. PubMed ID: 35611441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.